For Interventional Cardiologists
Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Report Demonstrate Benefit of Early Impella Cardiac Unloading
The final results of the physician-led NCSI Study demonstrate a 71% survival to discharge with greater than 90% native heart recovery when best practices are used, including placement of an Impella heart pump prior to revascularization (PCI).
Explore the Latest Presented Data From the National Cardiogenic Shock Initiative (NCSI) Study
- 71%
Survival1
- >90%
Native heart recovery at discharge1
NCSI Study is an independent, physician-led, national, multicenter initiative aimed at improving mortality in patients with AMI cardiogenic shock (AMICS).1 Based on the consistent finding of good survival outcomes with early hemodynamic support with Impella therapy from the IQ database and cVAD study, a best practices algorithm for the treatment of patients with AMICS was established. The NCSI Study algorithm includes identifying shock early, use of Impella therapy before PCI, reducing the use of inotropes, and the use of invasive hemodynamic monitoring to aid in escalation and weaning.
As of April 2021, 406 patients with AMI cardiogenic shock from 80 participating sites treated using Impella best practices demonstrated 71% survival at discharge with more than 90% native heart recovery.1
View Additional NCSI Study Resources
Efficacy and Safety of all Impella Heart Pump Use in Japanese Patients With Drug-Resistant Acute HF
Junya Ako, MD, presents the interim analysis of data from 819 patients from the Japanese Registry for Percutaneous VAD (J-PVAD). J-PVAD is an investigator-initiated, prospective study of all Impella use in Japan with the goal to safely and effectively disseminate the use of Impella with appropriate use guidance.
Conditions & Therapies
Education and Resources
Explore case reviews, clinical data, ongoing studies, best practice resources, patient management tips and more
Calculators and Tools
Access instant calculators for CPO/PAPI, heparin rate and AKI, and identify patients using the selection tool
References
- Basir, B., et al. (2021). SCAI Scientific Sessions
NPS-1340